ELVN · Enliven Therapeutics, Inc.

Enliven Therapeutics delivered improved financial results for the first quarter ended March 31, 2026, with net loss narrowing to $23.6 million from $28.5 million in the prior-year quarter, primarily due to a 17% reduction in R&D expenses to $20.7 million amid ongoing clinical execution, while G&A expenses rose modestly to $7.1 million. The company's robust balance sheet features $452.4 million in cash, cash equivalents, and marketable securities as of quarter-end, down slightly from $462.6 million at year-end 2025, supporting a cash runway into the first half of 2029 and funding key milestones without near-term dilution risk. CEO Rick Fair highlighted strategic momentum in chronic myeloid leukemia (CML), emphasizing ELVN-001's potential as a best-in-class ATP-competitive inhibitor targeting the BCR::ABL driver. Following positive initial Phase 1b data in January 2026, enrollment continues in the 80 mg once-daily expansion cohort (NCT05304377) for previously treated patients. The company reaffirmed 2026 catalysts: mid-year Phase 1 ENABLE data presentation, FDA interactions on dosing and Phase 3 design, and ENABLE-2 pivotal trial start in H2 2026. These updates signal disciplined cost management and clinical progress, positioning Enliven to address unmet CML needs across therapy lines.